Rezolute (RZLT) Net Equity Issued and Repurchased (2010 - 2022)
Rezolute (RZLT) posted Net Equity Issued and Repurchased of $12.3 million for Q3 2022, up 1232900.0% sequentially from $1000.0 in Q2 2022, and up 927.5% YoY from $1.2 million in Q3 2021.
Analysis
Rezolute (RZLT) Net Equity Issued and Repurchased (2010 - 2022) Analysis & Trends
Rezolute has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $12.3 million in Q3 2022.
- Quarterly Net Equity Issued and Repurchased rose 927.5% year-over-year to $12.3 million in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $12.3 million (up 952.05% YoY) and the FY2025 annual result came in at $76.2 million, up 55.44% from the prior year.
- Net Equity Issued and Repurchased rose to $12.3 million in Q3 2022 per RZLT's latest filing, from $1000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $49.5 million in Q4 2021 and troughed at -$49.6 million in Q1 2022.
- A 4-year average of $4.3 million and a median of $1.5 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2020 and 2021: Net Equity Issued and Repurchased soared 139.47% in 2020, then jumped 3202.53% in 2021.
- Over 4 years, Net Equity Issued and Repurchased stood at -$3.8 million in 2019, then surged by 139.47% to $1.5 million in 2020, then surged by 3202.53% to $49.5 million in 2021, then plunged by 75.11% to $12.3 million in 2022.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $12.3 million, $1000.0, and -$49.6 million for Q3 2022, Q2 2022, and Q1 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rezolute | 477.02 Mn | 477.02 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 12.33 Mn |
| Jun 30, 2022 | 61.70 Mn |
| Sep 30, 2021 | 2.69 Mn |
| Jun 30, 2021 | -41.00 Mn |
| Dec 31, 2020 | 1.50 Mn |
| Jun 30, 2020 | 24.05 Mn |
| Dec 31, 2019 | -20.00 Mn |
| Sep 30, 2019 | 20.00 Mn |
| Sep 30, 2017 | 4.50 Mn |
| Jun 30, 2017 | 3.78 Mn |
| Mar 31, 2017 | 4.50 Mn |
| Dec 31, 2016 | 3.67 Mn |
| Sep 30, 2016 | 2.69 Mn |
| Jun 30, 2016 | 5.36 Mn |
| Mar 31, 2016 | -2.00 Mn |
| Dec 31, 2015 | 2.00 Mn |
| Jun 30, 2015 | 1.41 Mn |
| Mar 31, 2015 | 2.84 Mn |
| Jun 30, 2014 | 3.96 Mn |
| Mar 31, 2014 | 4.97 Mn |